TABLE 2.
FICI values of exebacase used in addition to antibiotics in human serum
| Designation | Resistance | FICI scores with:a
|
|||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| DAP | VAN | NAF | OXA | CFZ | TLV | AZM | CLI | GEN | LNZ | LVX | SXT | ||
| NRS111 | MSSA | 0.375 | 0.500 | 0.563 | 0.625 | 0.375 | 0.500 | 0.500 | 0.500 | 0.625 | 0.500 | 0.500 | 1.031 |
| ATCC 29213 | MSSA | 0.375 | 0.500 | 0.500 | 0.313 | 0.500 | 0.500 | 0.375 | 0.250 | 1.000 | 0.500 | 0.375 | 1.000 |
| ATCC 49521 | MSSA | 0.375 | 0.375 | 0.500 | 0.507 | 0.500 | 0.500 | 0.375 | 0.250 | 0.508 | 0.375 | 0.500 | 0.750 |
| JMI 2559 | MSSA | 0.375 | 0.375 | 0.500 | 0.500 | 0.313 | 0.375 | 0.375 | 0.250 | 1.000 | 0.375 | 0.500 | 1.031 |
| JMI 3126 | MSSA | 0.500 | 0.375 | 0.500 | 0.500 | 0.500 | 0.375 | 0.375 | 0.313 | 1.000 | 0.375 | 0.500 | 1.031 |
| ATCC 43300 | MRSA | 0.250 | 0.500 | 0.625 | 0.500 | 0.375 | 0.500 | 0.500 | ND | 0.750 | 0.500 | 0.500 | 1.031 |
| JMI 227 | MRSA | 0.375 | 0.500 | 0.563 | 0.250 | 0.500 | 0.500 | 0.500 | 0.375 | 1.000 | 0.500 | 0.500 | 1.000 |
| JMI 1280 | MRSA | 0.313 | 0.375 | ND | ND | ND | 0.375 | 0.500 | ND | 0.750 | 0.500 | 0.500 | 0.625 |
| JMI 4789 | MRSA | 0.250 | 0.375 | 0.375 | 0.375 | 0.313 | 0.375 | 0.375 | 0.313 | 0.625 | 0.375 | 0.563 | 1.000 |
| MW2 | MRSA | 0.375 | 0.500 | 0.313 | 0.250 | 0.313 | 0.5 | 0.375 | 0.500 | 1.000 | 0.5 | 0.563 | 1.000 |
a
Mean FICI values were calculated based on the individual FICI values observed by row over at least 3 consecutive rows on each checkerboard panel. The FICI values are consistent with the following interactions: synergy, ≤0.5 (bold); additivity, >0.5 to ≤1 (italic); no interaction (indifference) >1 to ≤4 (shaded); antagonism, >4.